Arvinas

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis-targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Founded by Craig Crews, Ph.D., at Yale University, Arvinas has made incredible strides in targeted protein degradation research. This year marks a monumental milestone in Arvinas’ history as we celebrate our 10-year anniversary. Over the past decade, Arvinas has progressed multiple investigational drugs through clinical development programs, including vepdegestrant for ER+ HER2- breast cancer, ARV-393 targeting BCL6 for non-Hodgkin Lymphoma, and ARV-102 exploring LRRK2 for neurodegenerative disorders. We are deeply committed to the patients who suffer from these conditions, ensuring our pipeline aligns with their needs and the unmet medical challenges they face.